

Sydney, Australia. 1 February, 2018.

PHEBRA WELCOMES LISTING OF NARCAN ON PBS

Australian pharmaceutical manufacturer Phebra has welcomed the listing of the life-saving Narcan Injection (naloxone hydrochloride) on the Australian Pharmaceutical Benefits Scheme (PBS) today.

Narcan Injection is a medicine used to reverse the effects of overdoses of opioid drugs, and for the diagnosis of suspected acute opioid overdoses.

“We welcome the Federal Government’s decision to list Narcan Injection on the PBS,” Phebra’s Chief Executive Officer, Dr Mal Eutick, said today.

“Across Australia, Narcan Injection has been successfully utilised by frontline paramedics to save the lives of people suffering acute heroin overdoses, and reverse the fatal effects of opioid overdoses, including morphine and oxycodone.”

Narcan Injection will be available for reimbursement on the PBS from 1 February, 2018 (for Prescriber Bag Supply Only). Prescriber bags contain medicines that are provided without charge to doctors, who in turn can supply them free to patients for emergency use

About Phebra

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

At Phebra, we create critical medicines that save and improve lives.

Phebra media contact: Richard Lenarduzzi. 0411 254 390